VRDN | Viridian Therapeutics, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	12.92 - 13.75
52 Week Range	9.90 - 27.20
Beta	1.23
Implied Volatility	48.83%
IV Rank	33.83%
Day's Volume	532,037
Average Volume	946,837
Shares Outstanding	81,485,000
Market Cap	1,104,121,750
Sector	Healthcare
Industry	Biotechnology
IPO Date	2014-06-18

Valuation
Profitability
Growth
Health
P/E Ratio	-4.41
Forward P/E Ratio	-7.12
EPS	-3.07
1YR Price Target	40.00
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	94
Country	USA
Website	VRDN

Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate VRDN-001 is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) being developed for the potential treatment for patients with thyroid eye disease.

VRDN's peers: ALDX, CRNX, HALO, HRMY, HUMA, IMCR, INBX, JAZZ, KALV, KURA, LGND, MRSN, NUVL, PCVX, PLRX, PRTA, RCKT, ROIV, RYTM, SNDX, VCYT, DICE, ACLX, CYTK, GPCR, ICVX, RVMD, INZY, TERN, BPMC, ETNB, PTGX, MRUS, REPL, CERE, XENE, XNCR

*Chart delayed

Analyzing fundamentals for VRDN we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is passable. For more detailed analysis please see VRDN Fundamentals page.

Watching at VRDN technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on VRDN Technicals page.